Abstract
The issue of neuropathy in prediabetes and the metabolic syndrome has been controversial, the major reasons being the difficulty in defining neuropathy and the failure to recognize that a substantial proportion of patients with prediabetes have a sensory neuropathy without evidence of abnormalities in nerve conduction studies—the hallmark of the neurologists’ definition of what constitutes neuropathy. Secondly, there is a large cadre of people with neuropathy or neuropathic pain in whom careful studies of the criteria for prediabetes including impaired fasting glucose (IFG) and impaired glucose tolerance (IGT) as well as the lipid abnormalities of the metabolic syndrome (MS) such as elevated triglycerides and a low HDL-cholesterol have not been carried out. Taking these into consideration has vastly changed the appreciation of the relationship between neuropathy and the metabolic entities. Thus, it has been estimated that 24.6–62% of patients with chronic idiopathic symmetrical sensorimotor polyneuropathy (SPN) have prediabetes; as a corollary, of subjects with prediabetes, 11.2–24.3% exhibit SPN and 12.9–20.5% exhibit neuropathic pain. Population-based studies suggest a gradient for the prevalence of SPN, with the highest being in patients with diabetes, followed by IGT, IFG, and the lowest in normal glucose tolerance. The most sensitive test to evaluate glucose homeostasis is the oral glucose tolerance test (OGTT). The pathogenesis of neuropathy may be hyperglycemia, microvascular abnormalities, dyslipidemia, and the metabolic syndrome, with increasing evidence that oxidative and nitrosative stress may play a role. The characteristics of the neuropathy in prediabetes and the metabolic syndrome suggest that it may be a less severe neuropathy than in diabetes. Sensory modality findings prevail compared with motor, and small nerve fiber structure and function abnormalities may be the earliest findings. Diagnosis should rely on careful history and clinical examination, with emphasis on the evaluation of small fibers. A skin biopsy may be necessary to quantify intraepidermal nerve fiber density. An OGTT and fasting serum lipids should be performed in patients with idiopathic SPN to screen for prediabetes and the metabolic syndrome. Treatment should include hygienic measures such as diet and exercise. The only drug with potential for reversal of the neuropathy is Topiramate.
Keywords
- Heart Rate Variability
- Neuropathic Pain
- Oral Glucose Tolerance Test
- Impaired Glucose Tolerance
- Impaired Fasting Glucose
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsReferences
Vinik EJ, Hayes RP, Oglesby A, Bastyr E, Barlow P, Ford-Molvik SL, et al. The development and validation of the Norfolk QOL-DN, a new measure of patients’ perception of the effects of diabetes and diabetic neuropathy. Diabetes Technol Ther. 2005;7:497–508.
Boulton A, Vinik A, Arezzo J, Bril V, Feldman E, Freeman R, et al. Position statement: diabetic neuropathies. Diabetes Care. 2005;28(4):956–62.
Vinik AI, Ziegler D. Diabetic cardiovascular autonomic neuropathy. Circulation. 2007;115:387–97.
Smith AG, Singleton JR. Idiopathic neuropathy, prediabetes and the metabolic syndrome (Abstract). J Neurol Sci. 2006;242:9–14.
Rota E, Quadri R, Fanti E, Isoardo G, Poglio F, Tavella A, et al. Electrophysiological findings of peripheral neuropathy in newly diagnosed type II diabetes mellitus. J Peripher Nerv Syst. 2005;10:348–53.
Pittenger G, Mehrabyan A, Simmons K, Rice A, Dublin C, Barlow P, et al. Small fiber neuropathy is associated with the metabolic syndrome. Metab Syndr Relat Disord. 2005;3:113–21.
Dyck P, Clark V, Overland C, et al. Does impaired glycemia cause polyneuropathy and other diabetic complications? (Abstract). Peripher Nerve Soc. 2011;16(Suppl):S30.
Papanas N, Vinik AI, Ziegler D. Neuropathy in prediabettes: does the clock start ticking early? Nat Rev Endocrinol. 2011;7:682–90.
Vinik A, Ullal J, Parson HK, Casellini CM. Diabetic neuropathies: clinical manifestations and current treatment options. Nat Clin Pract Endocrinol Metab. 2006;2:269–81.
Pittenger GL, Ray M, Burcus NI, McNulty P, Basta B, Vinik AI. Intraepidermal nerve fibers are indicators of small-fiber neuropathy in both diabetic and nondiabetic patients. Diabetes Care. 2004;27:1974–9.
Sadosky A, McDermott AM, Brandenburg NA, Strauss M. A review of the epidemiology of painful diabetic peripheral neuropathy, postherpetic neuralgia, and less commonly studied neuropathic pain conditions. Pain Pract. 2008;8:45–56.
Tesfaye S, Boulton AJ, Dyck PJ, Freeman R, Horowitz M, Kempler P, et al. Diabetic neuropathies: update on definitions, diagnostic criteria, estimation of severity, and treatments. Diabetes Care. 2010;33:2285–93.
Ziegler D. Painful diabetic neuropathy: treatment and future aspects. Diabetes Metab Res Rev. 2008;24 Suppl 1:S52–7.
Boulton AJ, Malik RA, Arezzo JC, Sosenko JM. Diabetic somatic neuropathies. Diabetes Care. 2004;27:1458–86.
Vinik AI, Maser RE, Ziegler D. Neuropathy: the crystal ball for cardiovascular disease? Diabetes Care. 2010;33:1688–90.
Vinik A, Maser R, Ziegler D. Autonomic imbalance: prophet of doom or scope for hope? Diabet Med. 2011;28:643–51.
Mantyselka P, Ahonen R, Kumpusalo E, Takala J. Variability in prescribing for musculoskeletal pain in Finnish primary health care. Pharm World Sci. 2001;23:232–6.
Treede RD, Jensen TS, Campbell JN, Cruccu G, Dostrovsky JO, Griffin JW, et al. Neuropathic pain: redefinition and a grading system for clinical and research purposes. Neurology. 2008;70:1630–5.
Jensen MP, Chodroff MJ, Dworkin RH. The impact of neuropathic pain on health-related quality of life: review and implications. Neurology. 2007;68:1178–82.
Bouhassira D, Lanteri-Minet M, Attal N, Laurent B, Touboul C. Prevalence of chronic pain with neuropathic characteristics in the general population. Pain. 2008;136:380–7.
Vinik E, Paulson J, Ford-Molvik S, Vinik A. German-Translated Norfolk Quality of Life (QOL-DN) identifies the same factors as the English version of the tool and discriminates different levels of neuropathy severity. J Diabetes Sci Technol. 2008;2:1075–86.
Torrance N, Smith BH, Bennett MI, Lee AJ. The epidemiology of chronic pain of predominantly neuropathic origin. Results from a general population survey. J Pain. 2006;7:281–9.
Dieleman JP, Kerklaan J, Huygen FJ, Bouma PA, Sturkenboom MC. Incidence rates and treatment of neuropathic pain conditions in the general population. Pain. 2008;137:681–8.
Cornblath DR, Vinik A, Feldman E, Freeman R, Boulton AJ. Surgical decompression for diabetic sensorimotor polyneuropathy. Diabetes Care. 2007;30:421–2.
Smith AG, Russell J, Feldman EL, Goldstein J, Peltier A, Smith S, et al. Lifestyle intervention for pre-diabetic neuropathy. Diabetes Care. 2006;29:1294–9.
Ziegler D, Rathmann W, Dickhaus T, Meisinger C, Mielck A. Prevalence of polyneuropathy in pre-diabetes and diabetes is associated with abdominal obesity and macroangiopathy: the MONICA/KORA Augsburg Surveys S2 and S3. Diabetes Care. 2008;31:464–9.
Ziegler D, Rathmann W, Meisinger C, Dickhaus T, Mielck A. Prevalence and risk factors of neuropathic pain in survivors of myocardial infarction with pre-diabetes and diabetes. The KORA Myocardial Infarction Registry. Eur J Pain. 2009;13:582–7.
Ziegler D, Rathmann W, Dickhaus T, Meisinger C, Mielck A. Neuropathic pain in diabetes, prediabetes and normal glucose tolerance: the MONICA/KORA Augsburg Surveys S2 and S3. Pain Med. 2009;10:393–400.
Tesfaye S, Chaturvedi N, Eaton SE, Ward JD, Manes C, Ionescu-Tirgoviste C, et al. Vascular risk factors and diabetic neuropathy. N Engl J Med. 2005;352:341–50.
Lauria G, Hsieh S, Johansson O, Kennedy W, Leger J, Mellgren S, et al. European Federation of Neurological Societies/Peripheral Nerve Society Guideline on the Use of Skin Biopsy in the Diagnosis of Small Fiber Neuropathy. Report of a joint task force of the European Federation of Neurological Societies and the Peripheral Nerve Society. Eur J Neurol. 2010;17:903–12.
Lauria G, Bakkers M, Schmitz C, Lombardi R, Penza P, Devigili G, et al. Intraepidermal nerve fiber density at the distal leg: a worldwide normative reference study. J Peripher Nerv Syst. 2010;15:202–7.
Quattrini C, Tavakoli M, Jeziorska M, Kallinikos P, Tesfaye S, Finnigan J, et al. Surrogate markers of small fiber damage in human diabetic neuropathy. Diabetes. 2007;56:2148–54.
Tavakoli M, Quattrini C, Abbott C, Kallinikos P, Marshall A, Finnigan J, et al. Corneal confocal microscopy: a novel noninvasive test to diagnose and stratify the severity of human diabetic neuropathy. Diabetes Care. 2010;33:1792–7.
Zhivov A, Blum M, Guthoff R, Stachs O. Real-time mapping of the subepithelial nerve plexus by in vivo confocal laser scanning microscopy. Br J Ophthalmol. 2010;94:1133–5.
Parson HK, Nguyen VT, Boyd AL, Vinik A. CHEPS detects neuropathic changes earlier than traditional clinical measures. Diabetes. 2009;58(Suppl):829P.
Expert Committee on the Diagnosis and Classification of Diabete Mellitus. Report of the expert committee on the diagnosis and classification of diabetes mellitus (Abstract). Diabetes Care. 2003;26:S5–20.
DECODE Study Group, European Diabetes Epidemiology Group. Glucose tolerance and cardiovascular mortality: comparison of fasting and 2-hour diagnostic criteria. Arch Intern Med. 2001;161:397–405.
Qiao Q, Pyorala K, Pyorala M, Nissinen A, Lindstrom J, Tilvis R, et al. Two-hour glucose is a better risk predictor for incident coronary heart disease and cardiovascular mortality than fasting glucose. Eur Heart J. 2002;23:1267–75.
Hyvarinen M, Qiao Q, Tuomilehto J, Laatikainen T, Heine RJ, Stehouwer CD, et al. Hyperglycemia and stroke mortality: comparison between fasting and 2-h glucose criteria. Diabetes Care. 2009;32:348–54.
Ning F, Tuomilehto J, Pyorala K, Onat A, Soderberg S, Qiao Q. Cardiovascular disease mortality in Europeans in relation to fasting and 2-h plasma glucose levels within a normoglycemic range. Diabetes Care. 2010;33:2211–6.
Colagiuri S, Lee CM, Wong TY, Balkau B, Shaw JE, Borch-Johnsen K. Glycemic thresholds for diabetes-specific retinopathy: implications for diagnostic criteria for diabetes. Diabetes Care. 2011;34:145–50.
Sosenko JM, Kato M, Goldberg RB. Sensory function and albumin excretion according to diagnostic criteria for diabetes. Diabetes Care. 2004;27:1716–20.
Dyck PJ, Dyck PJ, Klein CJ, Weigand SD. Does impaired glucose metabolism cause polyneuropathy? Review of previous studies and design of a prospective controlled population-based study. Muscle Nerve. 2007;36:536–41.
Novella SP, Inzucchi SE, Goldstein JM. The frequency of undiagnosed diabetes and impaired glucose tolerance in patients with idiopathic sensory neuropathy. Muscle Nerve. 2001;24:1229–31.
Franklin GM, Kahn LB, Baxter J, Marshall JA, Hamman RF. Sensory neuropathy in non-insulin-dependent diabetes mellitus. The San Luis Valley Diabetes Study. Am J Epidemiol. 1990;131:633–43.
Singleton JR, Smith AG, Bromberg MB. Painful sensory polyneuropathy associated with impaired glucose tolerance. Muscle Nerve. 2001;24:1225–8.
Sumner CJ, Sheth S, Griffin JW, Cornblath DR, Polydefkis M. The spectrum of neuropathy in diabetes and impaired glucose tolerance. Neurology. 2003;60:108–11.
Smith AG, Singleton JR. The diagnostic yield of a standardized approach to idiopathic sensory-predominant neuropathy. Arch Intern Med. 2004;164:1021–5.
Singleton JR, Smith AG, Bromberg MB. Increased prevalence of impaired glucose tolerance in patients with painful sensory neuropathy. Diabetes Care. 2001;24:1448–53.
Hoffman-Snyder C, Smith BE, Ross MA, Hernandez J, Bosch EP. Value of the oral glucose tolerance test in the evaluation of chronic idiopathic axonal polyneuropathy. Arch Neurol. 2006;63:1075–9.
Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Report of the expert committee on the diagnosis and classification of diabetes mellitus (Abstract). Diabetes Care. 1997;20:1183–97.
Singleton JR et al. Diet and exercise counseling alone does not prevent long term neuropathy progression in IGTN (Abstract). American Academy of Neurology 59th Annual Meeting. May 4, 2007, Boston.
Sumner C, Sheth S, Griffin J, Cornblath D, Polydefkis M. The spectrum of neuropathy in diabetes and impaired glucose tolerance. Neurology. 2003;60:108–11.
Hughes RA, Umapathi T, Gray IA, Gregson NA, Noori M, Pannala AS, et al. A controlled investigation of the cause of chronic idiopathic axonal polyneuropathy. Brain. 2004;127:1723–30.
Nebuchennykh M, Loseth S, Jorde R, Mellgren SI. Idiopathic polyneuropathy and impaired glucose metabolism in a Norwegian patient series. Eur J Neurol. 2008;15:810–6.
Harris MI, Flegal KM, Cowie CC, Eberhardt MS, Goldstein DE, Little RR, et al. Prevalence of diabetes, impaired fasting glucose, and impaired glucose tolerance in U.S. adults. The Third National Health and Nutrition Examination Survey, 1988–1994. Diabetes Care. 1998;21:518–24.
Centers for Disease Control and Prevention (CDC). Prevalence of diabetes and impaired fasting glucose in adults, United States, 1999––2000. MMWR Morb Mortal Wkly Rep. 2003;52:833–7.
Russell JW, Feldman EL. Impaired glucose tolerance-does it cause neuropathy? Muscle Nerve. 2001;24(9):1109–12.
Kissel JT. Peripheral neuropathy with impaired glucose tolerance: a sweet smell of success? Arch Neurol. 2006;63:1055–6.
de Neeling JN, Beks PJ, Bertelsmann FW, Heine RJ, Bouter LM. Peripheral somatic nerve function in relation to glucose tolerance in an elderly Caucasian population: the Hoorn study. Diabet Med. 1996;13:960–6.
Grandinetti A, Chow DC, Sletten DM, Oyama JK, Theriault AG, Schatz IJ, et al. Impaired glucose tolerance is associated with postganglionic sudomotor impairment. Clin Auton Res. 2007;17:231–3.
Isak B, Oflazoglu B, Tanridag T, Yitmen I, Us O. Evaluation of peripheral and autonomic neuropathy among patients with newly diagnosed impaired glucose tolerance. Diabetes Metab Res Rev. 2008;24:563–9.
Fujimoto WY, Leonetti DL, Kinyoun JL, Shuman WP, Stolov WC, Wahl PW. Prevalence of complications among second-generation Japanese-American men with diabetes, impaired glucose tolerance, or normal glucose tolerance. Diabetes. 1987;36:730–9.
Shaw JE, Hodge AM, de Courten M, Dowse GK, Gareeboo H, Tuomilehto J, et al. Diabetic neuropathy in Mauritius: prevalence and risk factors. Diabetes Res Clin Pract. 1998;42:131–9.
Barr EL, Wong TY, Tapp RJ, Harper CA, Zimmet PZ, Atkins R, et al. Is peripheral neuropathy associated with retinopathy and albuminuria in individuals with impaired glucose metabolism? The 1999–2000 AusDiab. Diabetes Care. 2006;29:1114–6.
Eriksson KF, Nilsson H, Lindgarde F, Osterlin S, Dahlin LB, Lilja B, et al. Diabetes mellitus but not impaired glucose tolerance is associated with dysfunction in peripheral nerves. Diabet Med. 1994;11:279–85.
Mantyselka P, Miettola J, Niskanen L, Kumpusalo E. Glucose regulation and chronic pain at multiple sites. Rheumatology (Oxford). 2008;47:1235–8.
Mantyselka P, Miettola J, Niskanen L, Kumpusalo E. Chronic pain, impaired glucose tolerance and diabetes: a community-based study. Pain. 2008;137:34–40.
Feldman EL, Stevens MJ, Thomas PK, Brown MB, Canal N, Greene DA. A practical two-step quantitative clinical and electrophysiological assessment for the diagnosis and staging of diabetic neuropathy. Diabetes Care. 1994;17:1281–9.
Moghtaderi A, Bakhshipour A, Rashidi H. Validation of Michigan neuropathy screening instrument for diabetic peripheral neuropathy. Clin Neurol Neurosurg. 2006;108:477–81.
Vinik AI, Ullal J, Parson HK, Barlow PM, Casellini CM. Pioglitazone treatment improves nitrosative stress in type 2 diabetes. Diabetes Care. 2006;29:869–76.
Vinik AI, Maser RE, Mitchell BD, Freeman R. Diabetic autonomic neuropathy. Diabetes Care. 2003;26:1553–79.
Maser RE, Mitchell BD, Vinik AI, Freeman R. The association between cardiovascular autonomic neuropathy and mortality in individuals with diabetes: a meta-analysis. Diabetes Care. 2003;26:1895–901.
Ziegler D, Zentai CP, Perz S, Rathmann W, Haastert B, Doring A, et al. Prediction of mortality using measures of cardiac autonomic dysfunction in the diabetic and nondiabetic population: the MONICA/KORA Augsburg Cohort Study. Diabetes Care. 2008;31:556–61.
Task Force of the European Society of Cardiology, North American Society of Pacing and Electrophysiology. Heart rate variability: standards of measurement, physiological interpretation and clinical use. Circulation. 1996;93:1043–65.
Beijers HJ, Ferreira I, Bravenboer B, Dekker JM, Nijpels G, Heine RJ, et al. Microalbuminuria and cardiovascular autonomic dysfunction are independently associated with cardiovascular mortality: evidence for distinct pathways: the Hoorn Study. Diabetes Care. 2009;32:1698–703.
Diakakis GF, Parthenakis FI, Patrianakos AP, Koukouraki SI, Stathaki MI, Karkavitsas NS, et al. Myocardial sympathetic innervation in patients with impaired glucose tolerance: relationship to subclinical inflammation. Cardiovasc Pathol. 2008;17:172–7.
Gerritsen J, Dekker JM, TenVoorde BJ, Bertelsmann FW, Kostense PJ, Stehouwer CD, et al. Glucose tolerance and other determinants of cardiovascular autonomic function: the Hoorn Study. Diabetologia. 2000;43:561–70.
Singh JP, Larson MG, O’Donnell CJ, Wilson PF, Tsuji H, Lloyd-Jones DM, et al. Association of hyperglycemia with reduced heart rate variability (The Framingham Heart Study). Am J Cardiol. 2000;86:309–12.
Schroeder EB, Chambless LE, Liao D, Prineas RJ, Evans GW, Rosamond WD, et al. Diabetes, glucose, insulin, and heart rate variability: the atherosclerosis risk in communities (ARIC) study. Diabetes Care. 2005;28:668–74.
Wu JS, Yang YC, Lin TS, Huang YH, Chen JJ, Lu FH, et al. Epidemiological evidence of altered cardiac autonomic function in subjects with impaired glucose tolerance but not isolated impaired fasting glucose. J Clin Endocrinol Metab. 2007;92:3885–9.
Wu JS, et al. Epidemiological evidence of altered cardiac autonomic function in overweight but not underweight subjects. Int J Obes (Lond). 2008;32:788–95.
Stein PK, Barzilay JI, Domitrovich PP, Chaves PM, Gottdiener JS, Heckbert SR, et al. The relationship of heart rate and heart rate variability to non-diabetic fasting glucose levels and the metabolic syndrome: the Cardiovascular Health Study. Diabet Med. 2007;24:855–63.
Perciaccante A, Fiorentini A, Paris A, Serra P, Tubani L. Circadian rhythm of the autonomic nervous system in insulin resistant subjects with normoglycemia, impaired fasting glycemia, impaired glucose tolerance, type 2 diabetes mellitus. BMC Cardiovasc Disord. 2006;6:19.
Carnethon MR, Prineas RJ, Temprosa M, Zhang ZM, Uwaifo G, Molitch ME. The association among autonomic nervous system function, incident diabetes, and intervention arm in the Diabetes Prevention Program. Diabetes Care. 2006;29:914–9.
Vinik AI, Strotmeyer ES, Nakave AA, Patel CV. Diabetic neuropathy in older adults. Clin Geriatr Med. 2008;24:407–35; v.
Sugimoto K, Murakawa Y, Sima AA. Diabetic neuropathy—a continuing enigma. Diabetes Metab Res Rev. 2000;16:408–33.
Dobretsov M, Romanovsky D, Stimers JR. Early diabetic neuropathy: triggers and mechanisms. World J Gastroenterol. 2007;13:175–91.
Russell JW, Sullivan KA, Windebank AJ, Herrmann DN, Feldman EL. Neurons undergo apoptosis in animal and cell culture models of diabetes. Neurobiol Dis. 1999;6:347–63.
Edwards JL, et al. Diabetes regulates mitochondrial biogenesis and fission in mouse neurons. Diabetologia. 2010;53:160–9.
Burchiel KJ, Russell LC, Lee RP, Sima AA. Spontaneous activity of primary afferent neurons in diabetic BB/Wistar rats. A possible mechanism of chronic diabetic neuropathic pain. Diabetes. 1985;34:1210–3.
Garcia SF. Diabetic endothelial dysfunction: the role of poly(ADP-ribose) polymerase activation. Nat Med. 2001;7:108–13.
Heine RJ, Balkau B, Ceriello A, Del PS, Horton ES, Taskinen MR. What does postprandial hyperglycaemia mean? Diabet Med. 2004;21:208–13.
Su Y, Liu XM, Sun YM, Jin HB, Fu R, Wang YY, et al. The relationship between endothelial dysfunction and oxidative stress in diabetes and prediabetes. Int J Clin Pract. 2008;62:877–82.
Thrainsdottir S, Malik RA, Dahlin LB, Wiksell P, Eriksson KF, Rosen I, et al. Endoneurial capillary abnormalities presage deterioration of glucose tolerance and accompany peripheral neuropathy in man. Diabetes. 2003;52:2615–22.
Caballero AE, Arora S, Saouaf R, Lim SC, Smakowski P, Park JY, et al. Microvascular and macrovascular reactivity is reduced in subjects at risk for type 2 diabetes. Diabetes. 1999;48:1856–62.
Green AQ, Krishnan S, Finucane FM, Rayman G. Altered C-fiber function as an indicator of early peripheral neuropathy in individuals with impaired glucose tolerance. Diabetes Care. 2010;33:174–6.
Watcho P, Stavniichuk R, Ribnicky DM, Raskin I, Obrosova IG. High-fat diet-induced neuropathy of prediabetes and obesity: effect of PMI-5011, an ethanolic extract of Artemisia dracunculus L. Mediators Inflamm. 2010;2010:268547.
Stavniichuk R, Drel VR, Shevalye H, Vareniuk I, Stevens MJ, Nadler JL, et al. Role of 12/15-lipoxygenase in nitrosative stress and peripheral prediabetic and diabetic neuropathies. Free Radic Biol Med. 2010;49:1036–45.
Vincent AM, Hayes JM, McLean LL, Vivekanandan-Giri A, Pennathur S, Feldman EL. Dyslipidemia-induced neuropathy in mice: the role of oxLDL/LOX-1. Diabetes. 2009;58:2376–85.
Vincent AM, Hinder LM, Pop-Busui R, Feldman EL. Hyperlipidemia: a new therapeutic target for diabetic neuropathy. J Peripher Nerv Syst. 2009;14:257–67.
Davis TM, Yeap BB, Davis WA, Bruce DG. Lipid-lowering therapy and peripheral sensory neuropathy in type 2 diabetes: the Fremantle Diabetes Study. Diabetologia. 2008;51:562–6.
Herman RM, Brower JB, Stoddard DG, Casano AR, Targovnik JH, Herman JH, et al. Prevalence of somatic small fiber neuropathy in obesity. Int J Obes (Lond). 2007;31:226–35.
Parson H, Bridge J, Dublin C, Ullal J, Vinik A. African-Americans exhibit differences in neurovascular and endothelial dysfunction when compared to Caucasians. Diabetes. 2005;54:A220.
Smith AG, Rose K, Singleton JR. Idiopathic neuropathy patients are at high risk for metabolic syndrome. J Neurol Sci. 2008;273:25–8.
Smith AG, Singleton JR. Impaired glucose tolerance and neuropathy. Neurologist. 2008;14:23–9.
Singleton JR, Smith AG, Russell JW, Feldman EL. Microvascular complications of impaired glucose tolerance. Diabetes. 2003;52:2867–73.
Pacher P, Beckman JS, Liaudet L. Nitric oxide and peroxynitrite in health and disease. Physiol Rev. 2007;87:315–424.
Szabo C, Mabley JG, Moeller SM, Shimanovich R, Pacher P, Virag L, et al. Part I: pathogenetic role of peroxynitrite in the development of diabetes and diabetic vascular complications: studies with FP15, a novel potent peroxynitrite decomposition catalyst. Mol Med. 2002;8:571–80.
Virag L, Szabo E, Gergely P, Szabo C. Peroxynitrite-induced cytotoxicity: mechanism and opportunities for intervention. Toxicol Lett. 2003;140–141:113–24.
Obrosova IG, Drel VR, Oltman CL, Mashtalir N, Tibrewala J, Groves JT, et al. Role of nitrosative stress in early neuropathy and vascular dysfunction in streptozotocin-diabetic rats. Am J Physiol Endocrinol Metab. 2007;293:E1645–55.
Ziegler D, Sohr CG, Nourooz-Zadeh J. Oxidative stress and antioxidant defense in relation to the severity of diabetic polyneuropathy and cardiovascular autonomic neuropathy. Diabetes Care. 2004;27:2178–83.
Ceriello A, Assaloni R, Da RR, Maier A, Quagliaro L, Piconi L, et al. Effect of irbesartan on nitrotyrosine generation in non-hypertensive diabetic patients. Diabetologia. 2004;47:1535–40.
Vinik A, Parson H, Ullal J. The role of PPARs in the microvascular dysfunction in diabetes. Vascul Pharmacol. 2006;45:54–64.
Julius U, Drel VR, Grassler J, Obrosova IG. Nitrosylated proteins in monocytes as a new marker of oxidative-nitrosative stress in diabetic subjects with macroangiopathy. Exp Clin Endocrinol Diabetes. 2009;117:72–7.
Kellogg AP, Converso K, Wiggin T, Stevens M, Pop-Busui R. Effects of cyclooxygenase-2 gene inactivation on cardiac autonomic and left ventricular function in experimental diabetes. Am J Physiol Heart Circ Physiol. 2009;296:H453–61.
Gaede P, Vedel P, Larsen N, Jensen GV, Parving HH, Pedersen O. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med. 2003;348:383–93.
Rezania K, Soliven B, Rezai KA, Roos RP. Impaired glucose tolerance and metabolic syndrome in idiopathic polyneuropathy: the role of pain and depression. Med Hypotheses. 2011;76:538–42.
Petrova M, Townsend R, Teff KL. Prolonged (48-hour) modest hyperinsulinemia decreases nocturnal heart rate variability and attenuates the nocturnal decrease in blood pressure in lean, normotensive humans. J Clin Endocrinol Metab. 2006;91:851–9.
Ziegler D, Zentai C, Perz S, Rathmann W, Haastert B, Meisinger C, et al. Selective contribution of diabetes and other cardiovascular risk factors to cardiac autonomic dysfunction in the general population. Exp Clin Endocrinol Diabetes. 2006;114:153–9.
Licht CM, Vreeburg SA, van Reedt Dortland AK, Giltay EJ, Hoogendijk WJ, Derijk RH, et al. Increased sympathetic and decreased parasympathetic activity rather than changes in hypothalamic-pituitary-adrenal axis activity is associated with metabolic abnormalities. J Clin Endocrinol Metab. 2010;95:2458–66.
Chang CJ, Yang YC, Lu FH, Lin TS, Chen JJ, Yeh TL, et al. Altered cardiac autonomic function may precede insulin resistance in metabolic syndrome. Am J Med. 2010;123:432–8.
Masuo K, Kawaguchi H, Mikami H, Ogihara T, Tuck ML. Serum uric acid and plasma norepinephrine concentrations predict subsequent weight gain and blood pressure elevation. Hypertension. 2003;42:474–80.
Carnethon MR, Jacobs Jr DR, Sidney S, Liu K. Influence of autonomic nervous system dysfunction on the development of type 2 diabetes: the CARDIA study. Diabetes Care. 2003;26:3035–41.
Putz Z, Tabak AG, Toth N, Istenes I, Nemeth N, Gandhi RA, et al. Noninvasive evaluation of neural impairment in subjects with impaired glucose tolerance. Diabetes Care. 2009;32:181–3.
Smith AG, Ramachandran P, Tripp S, Singleton JR. Epidermal nerve innervation in impaired glucose tolerance and diabetes-associated neuropathy. Neurology. 2001;57:1701–4.
Hays AP. Utility of skin biopsy to evaluate peripheral neuropathy. Curr Neurol Neurosci Rep. 2010;10:101–7.
Peltier A, Smith AG, Russell JW, Sheikh K, Bixby B, Howard J, et al. Reliability of quantitative sudomotor axon reflex testing and quantitative sensory testing in neuropathy of impaired glucose regulation. Muscle Nerve. 2009;39:529–35.
Tavakoli M, Marshall A, Pitceathly R, Fadavi H, Gow D, Roberts ME, et al. Corneal confocal microscopy: a novel means to detect nerve fibre damage in idiopathic small fibre neuropathy. Exp Neurol. 2010;223:245–50.
Parson H, Orciga M, Huertas H, Vinik A. Evidence of early involvement of A delta and C-fibers in proximal sites in type 2 diabetes Abstract No. 14-LB. American Diabetes Association 71st Scientific Session, June 24–28, 2011, San Diego, California.
Selvarajah D, Rao G, Tesfaye S. Diagnosing diabetic peripheral neuropathy using Sudoscan, a new, rapid method of assessing Sudometer function Abstract No. 2119-PO. American Diabetes Association 71st Scientific Session, June 24–28, 2011, San Diego, California.
Gong Q, et al. Long-term effects of a randomised trial of a 6-year lifestyle intervention in impaired glucose tolerance on diabetes-related microvascular complications: the China Da Qing Diabetes Prevention Outcome Study. Diabetologia. 2011;54:300–7.
Gaede P, Vedel P, Larsen N, Jensen G, Parving H, Pedersen O. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med. 2003;348:383–93.
Boyd A, Casellini C, Vinik E, Vinik A. Quality of life and objective measures of diabetic neuropathy in a prospective placebo controlled trial of ruboxistaurin and topiramate. J Diabetes Sci Technol. 2011;5(3):714–22.
Boyd AL, Barlow P, Pittenger G, Simmons K, Vinik A. Topiramate improves neurovascular function, epidermal nerve fiber morphology, and metabolism in patients with type 2 diabetes mellitus. Diabetes Metab Syndr Obes. 2010;3:431–7.
Colberg S, Swain D, Vinik A. Use of heart rate reserve and rating of perceived exertion to prescribe exercise intensity in diabetic autonomic neuropathy. Diabetes Care. 2003;26:986–90.
Colberg SR, Stansberry KB, McNitt PM, Vinik AI. Chronic exercise is associated with enhanced cutaneous blood flow in type 2 diabetes. J Diabetes Complications. 2002;16:139–45.
Michalsen A, Knoblauch NT, Lehmann N, Grossman P, Kerkhoff G, Wilhelm FH, et al. Effects of lifestyle modification on the progression of coronary atherosclerosis, autonomic function, and angina—the role of GNB3 C825T polymorphism. Am Heart J. 2006;151:870–7.
Howorka K, Pumprla J, Haber P, Koller-Strametz J, Mondrzyk J, Schabmann A. Effects of physical training on heart rate variability in diabetic patients with various degrees of cardiovascular autonomic neuropathy. Cardiovasc Res. 1997;34:206–14.
Motooka M, Koike H, Yokoyama T, Kennedy NL. Effect of dog-walking on autonomic nervous activity in senior citizens. Med J Aust. 2006;184:60–3.
Ziegler D, Schatz H, Conrad F, Gries FA, Ulrich H, Reichel G. Effects of treatment with the antioxidant alpha-lipoic acid on cardiac autonomic neuropathy in NIDDM patients. A 4-month randomized controlled multicenter trial (DEKAN Study). Deutsche Kardiale Autonome Neuropathie. Diabetes Care. 1997;20:369–73.
Ziegler D, Weise F, Langen KJ, Piolot R, Boy C, Hubinger A, et al. Effect of glycaemic control on myocardial sympathetic innervation assessed by metaiodobenzylguanidine scintigraphy: a 4-year prospective study in IDDM patients. Diabetologia. 1998;41:443–51.
Shun C, et al. Brain. Skin denervation in type 2 diabetes: correlations with diabetic duration and functional impairments. 2004;127:1593–605.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2012 Springer Science+Business Media New York
About this chapter
Cite this chapter
Vinik, A.I., Nevoret, ML. (2012). Neuropathy in Prediabetes and the Metabolic Syndrome. In: LeRoith, D. (eds) Prevention of Type 2 Diabetes. Springer, New York, NY. https://doi.org/10.1007/978-1-4614-3314-9_8
Download citation
DOI: https://doi.org/10.1007/978-1-4614-3314-9_8
Published:
Publisher Name: Springer, New York, NY
Print ISBN: 978-1-4614-3313-2
Online ISBN: 978-1-4614-3314-9
eBook Packages: MedicineMedicine (R0)